Risks
4 risks
Risk Intelligence
US tariff uncertainty on pharma products
View Risks →Gland Pharma Limited — Q1 FY26
Gland Pharma reported a strong Q1 FY26 with consolidated revenue of ₹1,556 crore (+7% YoY) and EBITDA of ₹368 crore (+39% YoY), driving EBITDA margin expansion of 500 bps to 24%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported a strong Q1 FY26 with consolidated revenue of ₹1,556 crore (+7% YoY) and EBITDA of ₹368 crore (+39% YoY), driving EBITDA margin expansion of 500 bps to 24%. PAT surged 50% YoY to ₹216 crore. The base business EBITDA margin improved to 35% (vs 29% last year), while the key highlight was Synergia achieving breakeven after several quarters, with revenue of €48 million and gross margin of 80%. Management guided for mid-teens revenue growth for the full year, driven by new product launches (including GLP-1 pen/cartridge capacity expansion from 40M to 140M units by March 2026) and a strong pipeline in complex injectables and RTU bags. Key risks include potential US tariffs on pharma (though generics may be exempt) and the seasonally weaker Q2 due to summer shutdown at Synergia.
ग्लैंड फार्मा ने पहली तिमाही (Q1 FY26) में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई ₹1,556 करोड़ रही, जो पिछले साल से 7% ज़्यादा है। कमाई पर खर्च घटाने के बाद बचा मुनाफा (EBITDA) ₹368 करोड़ रहा, जो 39% बढ़ा। इससे मुनाफे की दर (EBITDA margin) 24% हो गई, जो पिछले साल से 5% ज़्यादा है। शुद्ध मुनाफा (PAT) 50% बढ़कर ₹216 करोड़ हो गया। खास बात यह है कि सिनर्जिया ने कई तिमाहियों बाद घाटा खत्म कर मुनाफा कमाया। कंपनी को इस साल अच्छी बढ़ोतरी की उम्मीद है, खासकर नए उत्पादों (जैसे GLP-1 पेन) से। लेकिन अमेरिकी टैरिफ और गर्मी की छुट्टियों के कारण अगली तिमाही कमज़ोर रह सकती है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Synergia Revenue
€48M
+20% YoY
Synergia achieved breakeven this quarter, with revenue of €48 million and gross margin improving to 80% from 78%.
GLP-1 Pen/Cartridge Capacity
140M units
+250% YoY
Capacity expanding from 40M to 140M units, with new line ready for commercialization by March 2026.
US Revenue Contribution
49%
-2pp YoY
US revenue was ₹744 crore, down 2% YoY due to timing of large SKU supplies; ex-enoxaparin, growth was ~11%.
Base Business EBITDA Margin
35%
+600bps YoY
Excluding Synergia, base business EBITDA margin improved to 35% from 29% last year, driven by gross margin expansion.
Fast read
Guidance and risk preview
Management expects consolidated revenue to grow in mid-teens for the full year, driven by new product launches and market expansion.
Potential US tariffs on pharmaceutical imports could impact pricing and margins, though generics may be exempt.
View Risks →